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Abstract
Background: Tandem mass spectrometry (MS/MS) technology has been applied to identify proteins, as an ultimate
approach to confirm the original genome annotation. To be able to identify gene fusion proteins, a special
database containing peptides that cross over gene fusion breakpoints is needed.
Methods: It is impractical to construct a database that includes all possible fusion peptides originated from
potential breakpoints. Focusing on 6259 reported and predicted gene fusion pairs from ChimerDB 2.0 and Cancer
Gene Census, we for the first time created a database CanProFu that comprehensively annotates fusion peptides
formed by exon-exon linkage between these pairing genes.
Results: Applying this database to mass spectrometry datasets of 40 human non-small cell lung cancer (NSCLC)
samples and 39 normal lung samples with stringent searching criteria, we were able to identify 19 unique fusion
peptides characterizing gene fusion events. Among them 11 gene fusion events were only found in NSCLC
samples. And also, 4 alternative splicing events were characterized in cancerous or normal lung samples.
Conclusions: The database and workflow in this work can be flexibly applied to other MS/MS based human
cancer experiments to detect gene fusions as potential disease biomarkers or drug targets.
Introduction
Cancers arise as the result of genomic changes that
occur in DNA sequences of cells [1]. These changes
include single nucleotide variation (SNV), small inser-
tion and deletion (INDEL), structural variation (SV)
including deletion, duplication, inversion, translocation
etc., and so on. Non-synonymous SNVs which could
cause the variation of amino acid in protein have always
been the interest of disease related research in genomics
studies [2,3]. Recently, some researchers also tried to
identify and validate the non-synonymous SNV in the
proteomics level from tandem mass spectrometry data
[4,5]. Their difficulty rooted in the present situation that
the analysis of mass spectrometry data mainly relied on
the database searching strategy. If the mutated peptide
were not included in the database, they could not be
identified. As for more complicated gene structure varia-
tions that cause change of protein translation, such as
gene fusion, alternative splicing, it is even more difficult
to identify and validate from proteomics level.
SVs that may concatenate two different genes to form
a new gene and new protein product are named gene
fusions. Fusion genes are often oncogenes, such as BCR:
ABL in chronic myeloid leukaemia (CML), TMPRSS2:
ERG in prostate cancer, EML4:ALK in non-small-cell
lung cancer (NSCLC) and so on. Among them the first
discovered and most famous fusion gene is the BCR:
ABL. ABL and BCR are normal genes on chr9 and
chr22 respectively and ABL encodes a tyrosine kinase
whose activity is tightly regulated. However, when the
translocation occurred between chr9 and chr22, a phos-
phate group was added to tyrosine. The result of this
event is the formation of BCR:ABL whose activity was
deregulated. BCR:ABL and many other fusion genes
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exert their tumorigenic action mainly through two
mechanisms. The first one is that one gene is concate-
nated to the promoter of the other gene, and the
expression of the downstream gene is affected and regu-
lated by the promoter of the upstream gene. The second
one is that partial sequence of one gene was concate-
nated to the other and they altogether give rise to a new
protein product. Obviously, the second mechanism
should give opportunity to MS/MS to identify those
new proteins if only the targeted fusion peptides could
be included in the searched database when identifying
proteins from mass spectrometry data, just as the dis-
covery of the SNV peptides [4,5].
The technology of identifying novel proteins and even-
tually explaining or discovering new events on genome
annotation is called proteogenomics [6]. Through pro-
teogenomics genome variation events such as new pro-
tein coding region, new alternative splicing, frame-shift
translation, N-terminal methionine excision, signal pep-
tides etc. can be studied on both levels of proteomics
and genomics. This strategy has already been used in
many species including human [7], mouse [8], arabidop-
sis [9] and many bacteria [10] to help improve genome
annotation. Recently the technology has been applied in
cancer proteomics data [4]. However, it has not been
applied to identify cancer fusion proteins yet.
Lung cancer is both one of the most commonly diag-
nosed cancers worldwide (1.61 million, 12.7% of the
total) and one of the most common causes of cancer
death (1.38 million, 18.2% of the total) [11]. It can be
classified into two main types: small-cell lung carci-
noma (SCLC) and non-small-cell lung carcinoma
(NSCLC) and NSCLC includes three main subtypes:
adenocarcinoma (ADC, about 40% of lung cancers),
squamous-cell lung carcinoma (SCC, about 30% of
lung cancers), and large-cell lung carcinoma (about 9%
of lung cancers). Lung cancer is most commonly
caused by long-term exposure to tobacco smoke, in
genetics level recurrent somatic SNVs have been iden-
tified, including those in KRAS, LRP1B, NF1 and so on
[12]. Multiple gene fusions, such as EML4:ALK, TFG:
ALK, SLC34AL:ROS, CD74:ROS have also been charac-
terized by PCR or next generation sequencing (NGS)
technology [13,14].
To study more thoroughly the possible impact of gene
fusions on the genetics of lung cancer, here in this work
we used proteogenomics strategy to identify gene fusion
proteins based on high-throughput lung cancer proteo-
mics data. To achieve our goal the most important job
is to construct a searchable fusion peptide database.
From our previous work on construction of searchable
peptide database covering all possible splicing events in
mouse [8], we knew that it would be impractical to con-
struct a database that includes all possible fusion
peptides originated from potential breakpoints. There-
fore we utilized the information of fusion gene pairs col-
lected from published papers in Cancer Gene Census
[15], and information from database Chimer DB 2.0 [16]
which contains some predicted gene pairs from DNA-
Seq, RNA-Seq or EST data, and constructed CanProFu
— a specific database for identifying potential gene
fusion peptides and alternative splicing peptides based
on human mass spectrometry data. Through strict
searching strategy, we identified some fusion and spli-
cing events that demonstrate distinctive distribution
among ADC, SCC or Normal samples. Our work pipe-
line is illustrated in Figure 1.
Results
CanProFu - the fusion peptide database
From Cancer Gene Census [15] and Chimer DB 2.0
[16], we obtained altogether 6259 non-redundant gene
pairs (6174 genes) that can form fusion genes, these are
the candidates to construct our potential fusion peptide
database — CanProFu. All the exon sequences, and also
the additional information such as exon ID, gene ID,
exon position, gene position, gene symbol et al, were
obtained from Ensembl Genes 61 using BioMart [17].
We considered only fusion events with break points of
both the original pair of genes located in intron regions.
The resulted CanProFu is composed of five types of
peptides: Fusion (close to five million peptides), Splicing
(close to two million peptides), Annotated (about 130
thousand proteins), Contaminated (248 peptides) and
Reversal (about 7 million peptides). The total sequences
included in CanProFu are about 14 million. Detailed
numbers are provided in Additional File 1.
Fusion peptides and splicing peptides identified in lung
cancer based on mass spectrometry data
Mass spectrometry raw data of 20 human lung squa-
mous cell carcinoma, 20 lung adenocarcinoma, and 39
normal lung tissues [31] were downloaded from http://
ProteomeCommons.org Tranche network [18], and were
converted to MGF format by ProteoWizard msconvert
tool [19] before submitted to search engines. Two
search engines, X!Tandem and Omssa, were applied to
the above three types of mass spectrometry data to
identify fusion peptides and splicing peptides. After data
quality control and cross-reference validation, we con-
sider a peptide as truly reliable only if it passes at least
one of the following two criteria: identified by both
search engines, or conserved in other species other than
homo sapiens (for splicing peptides only). Table 1 shows
final 19 fusion peptides and 4 splicing peptides that
passed such criteria. The most reliable peptides would
be those identified as fully digested with no mis-clea-
vage, and by both search engines.
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Data quality control and cross-reference validation of the
identified fusion peptides and splicing peptides
False positive discovery is the main obstacle facing iden-
tification of peptides from customized database search-
ing. To antagonize this issue in our study we applied
data quality control and cross-reference validation.
Quality control was achieved by applying two search
engines on the same dataset, and setting very stringent
local FDR (false discovery rate) control, and other data
quality check at the level of amino acids such as num-
ber, digestion status and mis-cleavage status. Cross-
reference validation was performed in two ways: conser-
vation blast to sequences from other species than homo
sapiens(for splicing peptides) and manual check of the
original mass spectra.
To reduce false positives and improve the reliability of
identified peptides, two popular search engines, X!Tan-
dem [20] and Omssa [21] were used to score each spec-
trum to the peptides. Other than using normal FDR
value such as 0.01, we minimized FDR control to 10-6 in
practice, as described in our previous work [8]. Only
peptides with at least three amino acids identified along
each side of a fusion/splicing point were retained. All
the identified peptides were further classified into three
types at decreasing reliability: A) full digestion and no
mis-cleavage, the most reliable; B) full digestion and one
mis-cleavage; C) semi-digestion. As a result, X!Tandem
identified 13780 peptides, among them 13503(97.99%)
were Annotated, 203(1.47%) were Fusion and 74(0.54%)
were Splicing. Omssa identified 8101 peptides, among
them 7894(97.44%) were Annotated, 167(2.06%) were
Fusion and 40(0.49%) were Splicing. 25 Fusion peptides
and 5 Splicing peptides were identified by both X!Tan-
dem and Omssa. We keep these as candidate identified
peptides. The venn diagram is displayed in Additional
File 2.
Then we performed conservation analysis by blasting
all the peptides to NCBI non-redundant database. If a
Figure 1 Workflow for identifying gene fusion and splicing events from MS/MS spectrometry data. A) The external information used for
constructing the searchable database B) Five components of the searchable database C) MS/MS data from 40 non-small cell lung cancer(NSCLC)
samples and 39 normal lung samples D) Two search engines and strict false discovery rates (FDR) were used to identify the peptides E) More
creditable results from the intersection of two search engines and the conservation information F) The distribution of the identified fusion or
splicing events among the caner and normal samples.
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fusion or splicing peptide could be found in other spe-
cies, even if they were only identified by one of the
search engines, they were included as candidate identi-
fied peptides. Additional File 3 demonstrates such an
example. By this way, no fusion peptide was found to be
conservative among other species (which is understand-
able, fusion peptides are hardly consistent even among
one species) (total up still be 25) and one more splicing
peptide was saved (total up to 6).
Then we went on to manually check each of the origi-
nal spectra for these candidate identified fusion and spli-
cing peptides. We observed that sometimes even one
same peptide was identified by both search engines, but
the original spectra were completely different. These
peptides (6 out of 25 Fusion peptides and 2 out of 6
Splicing peptides) may not be fully credible and were
ruled out from the following analysis (Additional File 4).
Therefore Table 1 shows the final results of 19 fusion
peptides and 4 splicing peptides.
The gene fusion or splicing events could have
occurred either in the DNA level or in the RNA level.
The original DNA sequences which were translated to
identified fusion and splicing peptides could be obtained
by backtracking, and the involved exons are shown
(Figure 2 and Figure 3).
The distribution of the fusion peptides and splicing
peptides among squamous-cell lung carcinoma (SCC),
adenocarcinoma (ADC), and normal lung tissue
To determine whether each peptide was from small cell
lung carcinoma (SCC), adenocarcinoma (ADC), or nor-
mal lung samples (Normal), we went back to check
from which type of samples the original mass spectrum
came from. Among those 23 peptides (19 of the Fusion
peptides and 4 of the Splicing peptides), 8 peptides were
only detected in SCC, 2 peptides were only detected in
ADC, and 3 peptides were only found in Normal. See
Figure 4 and Additional File 5 for detail.
Functional analyses of MYH9:ALK fusion peptide
We found that the peptide which characterizes the
fusion event between MYH9 and ALK genes only existed
in SCC and ADC, and higher copies were found in SCC
(Figure 4). MYH9 normally locates on the complement
strand of chr22, and encodes a conventional non-muscle
myosin which was reported to be involved in several





Fusion EQISENPTEATDIDFIR PTPN12:HSP90AA1 5 9 A D
Fusion VIFMDGNGYISAAELR HN1:CALM1 9 3 A D
Fusion IMGIPEEEQMVLSR MYH9:ALK 4 5 A D
Fusion ENVGLEEEQQALQK PDIA6:TPM2 3 6 A D
Fusion AVFVDLEPTVIGGGSVR TUBA1C:PCGF2 5 3 A D
Fusion AAEDDEFTHLYTLIVRPDNTYEVK GPR115:CALR 2 5 A D
Fusion EDSELLISSWLVTDR DOCK9:BAZ1A 3 2 A D
Fusion AVQQELDDLLVDLDHQR TGFBI:MYH9 2 2 A D
Fusion QVTNFLSSINEEITPR FGFR1:BCR 1 2 A D
Fusion ERPAPGQAVLSGGTTMYPGIADR ACO2:ACTB 1 2 A D
Fusion LSAASTWLEDEGVGATTVLFK HYOU1:HMGA1 1 1 A D
Fusion AVFVDLEPTVIEPVR TUBA1A:PTPN13 1 1 A D
Fusion EAREVIELTK CLCN3:SMNDC1 4 5 B D
Fusion NKAEILELAGNAAR ATP2B4:H2AFY 3 3 B D
Fusion EAKGESGPSGPAGPTGAR USP6:COL1A1 3 2 B D
Fusion GRTGDAGPVGEAGAAGPAGPAGPR COL1A1:COL1A2 1 2 B D
Fusion AKQEPEVNGGSGDAVPSG
NEVSENMEEEEEALSLMK
NASP:WIPF1 1 2 B D
Fusion AHSEEPMEIFVDDETK ESPN:BAT1 4 6 C D
Fusion TTGIVMDSGDGVTHTVPDASRVP ACTB:GNAS 1 1 C D
Splicing INGGGGGSVPGIER HNRNPM 12 0 A
Splicing GDVEEDETIPDSPSVLETIR TNPO1 2 6 A D
Splicing GGSGYGDLGGPIITTQVTIPK HNRNPK 3 3 A D
Splicing RVEDEVNSGVGQDGSLLSSPFLK SLC35A4 2 2 B D
The two genes in the fusion events are separated by colon. The value in the columns of No.X!Tandem and No.Omssa column are the number of spectra of the
peptide. A indicates that the peptide was fully digested by trypsin and with no mis-cleavage. B indicates that the peptide was fully digested but with one mis-
cleavage. C indicates that the peptide was semi-digested. D indicates that the peptide was identified by at least one same spectrum in both X!Tandem and
Omssa search engines.
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important functions, such as cytokinesis, cell motility
and maintenance of cell shape. Defects in this gene have
been associated with non-syndromic sensorineural deaf-
ness autosomal dominant type 17 [22], Epstein syn-
drome and so on [23]. ALK normally locates on the
complement strand of chr2, and encodes a receptor tyr-
osine kinase. Many translocations have been found with
this ALK gene, including EML4:ALK which is responsi-
ble for approximately 3-5% of non-small-cell lung can-
cer(NSCLC) [13], RANBP2:ALK, TPM4:ALK in
inflammatory myofibroblastic tumor [24,25], NPM1:
ALK, ATIC:ALK, TFG:ALK in anaplastic large cell lym-
phoma [26-29], and so on. The MYH9:ALK which is
highlighted in our work was also reported by Lamant et
al in anaplastic large cell lymphoma[30], but never in
lung cancer before. It may be a novel gene fusion event
that plays important role in lung cancer development,
and may merit further experimental verification.
Discussion
In this work, we constructed a database for the purpose
of identifying fusion peptides from human cancer pro-
teomics data based on mass spectrometry. We demon-
strated the usage of this database by identifying
candidate fusion proteins from raw mass spectrometry
data generated on human non-small cell lung cancer
(NSCLC) subtype samples. Two popular search engines
X!Tandem and Omssa were applied. After data quality
control and validation by other reference information
such as sequences at DNA and RNA level, we eventually
identified 19 fusion peptides and 4 splicing peptides, and
analyzed their distribution in the original NSCLC sub-
types, i.e., squamous cell carcinoma (SCC), adenocarci-
noma (ADC), in comparison with that in normal lung
sample controls (Normal). MYH9:ALK fusion peptide
was found to be a novel fusion peptide that occurred in
SCC and ADC. The fusion of MYH9 and ALK gene
which resulted in a new protein product might have
been an important genomic structural variation that
occurred in the development of NSCLC.
Currently genome variation events such as single
nucleotide variation (SNV) and structural variation (SV)
such like fusion genes are mostly studied by whole gen-
ome sequencing (WGS) or RNA sequencing. They have
the advantage of being high-throughput. However the
Figure 3 One example of alternative splicing event in HNRPM.
ENSE00001307025 is joined with ENSE00000909993. Both the DNA
and peptide sequences are shown, with the identified peptide
displayed in a red rectangle. The splicing point is separated by
different colors.
Figure 2 One example of gene fusion event between MYH9
and ALK. ENSE00001745962 of ALK is joined with
ENSE00001600096 of MYH9. Both the DNA and peptide sequences
are shown, with the identified peptide displayed in a red rectangle.
The fusion point is separated by different colors.
Figure 4 Distribution of the identified fusion or splicing events
among subtypes of NSCLC: SCC (squamous cell carcinoma),
ADC (adenocarcinoma), and Normal lung samples. The two
genes in the fusion events are separated by colon and displayed in
magenta and the genes related to alternative splicing are displayed
in green. The value in the color bar indicates the number of
spectrums of the identified peptide.
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disadvantage is that it is uncertain that SNVs or SVs
may actually affect disease development by causing final
protein product change. To address this, proteomics
data must be checked closely. Proteogenomics is such a
technique that starts from protein level and traces back
to genomic events. It has been tested to help annotate
normal genomes across multiple species, by first identi-
fying peptide sequences from mass spectrometry data,
and then mapping back to discover the original protein
coding events on genome sequences [7,31]. Database
searching algorithm is the most often used technique
[20,32-34], de novo peptide identification algorithms
have also been actively developed [35,36].
Cancer is often referred as a genomic disease, since
genomic instability is one major character that leads to
malignant cell development. Genomic instability such as
single nucleotide mutation, translocation, gene fusion,
gene copy number variation etc. causes gene expression
change and ultimately changes in proteins. In cancer
proteomics field, proteogenomics has been applied to
identify SNVs that result in single amino acid variations
(SAVs), by constructing specialized database containing
SAVs and developing more stringent database searching
algorithm [4,5]. However proteogenomics faces substan-
tial challenge when applied to identify more complicated
gene structural variations. One gene can have so many
translational products, even just by normal alternative
splicing [8], not to mention other structural variation
such as gene fusions and translocations. To include
gene structural variation in any peptide database would
increase the search space and false discovery rate, and
de novo peptide identification suffers from even lower
accuracy. That is why SVs have rarely been studied
based on mass spectrometry data.
In this work we presented a primary effort on identify-
ing SV events that resulted in abnormal peptides from
cancer mass spectrometry data. To achieve this goal, the
first step is to construct a customized database. To
make our goal specific and the database at controllable
scale, we focused on the purpose of identifying only
fusion peptides or splicing peptides. One reason for our
experimental design is that gene fusions have been said
to occur in all malignancies and account for 20% of
human cancer morbidity but all currently reported gene
fusions were discovered only through next-generation
sequencing in DNA or RNA level or time consuming
and small scale experiments in particular proteins[37].
One advantage of the wide study though is that there
are multiple resources anchoring gene fusion events that
have been studied or predicted in various solid and
hematological malignancies, such as ChimerDB [16] and
CancergeneCensus [15]. These resources provided us
with more reliable materials to construct a cancer fusion
peptide database — CanProFu. We applied more than
one database searching algorithm and practiced strin-
gent false discovery rate controlling when testing our
database with lung cancer mass spectrometry data.
There are limitations to our work. The samples of
subtypes of non-small cell type lung cancer were pooled
for mass spectrometry, this made the experimental veri-
fication more unfeasible than if the original individual
samples were accessible. Our constructed CanProFu is
of restricted size and might miss some cancer fusion
events that are not included in this primary database.
Although we set FDR controlling to be very strict we
did not develop special algorithm to antagonize high
false discovery rate. All these could be improved in
future endeavors, and it may be mentioned that
although peptides identified from this work were not
experimentally verified because of non-accessibility to
original samples, we did identify some splicing peptides
from cell line mass spectrometry data and experimen-
tally verified them, which could be a proof of the applic-
ability of our database (data unpublished yet).
Proteogenomics has come a long way in its application
of identifying more proteins and explaining more geno-
mic events. Experimentally protein identification cover-
age has been increased remarkably by industrial
development of instruments and improved experimental
techniques such as protein digestion by more than one
protease [38]. Computationally the construction of more
comprehensive database, and attempts to equalize target
and decoy database to increase sensitivity when using
traditional FDR controlling [39], or modified algorithms
of search engines to adapt to different purposes [40]
also expanded a great deal the peptide and protein iden-
tification rate. Therefore in the future, cancer genomic
variations such as gene fusions would be more feasibly
identified from proteomics level, based on more exten-
sive mass spectrometry data, expanded customized pro-
tein databases, and optimized search engines and
algorithms. This would help understand cancer develop-
ment mechanisms better, and bring cancer biomarker
discovery closer to clinical applications.
Conclusion
For the purpose of identifying cancer fusion events, we
constructed a cancer fusion peptide sequence database—
CanProFu. Applying mass spectrometry data from 40
non-small cell lung cancer(NSCLC) samples and 39 nor-
mal lung tissue controls to search in CanProFu, 19 fusion
peptides and 4 splicing peptides were identified. MYH9:
ALK fusion peptide was newly found and only existed in
NSCLC. The CanProFu database and workflow in this
work can be flexibly applied to other MS/MS based
human cancer experiments to detect gene fusions as
potential disease biomarkers and help improve under-
standing of the related cancer mechanism.
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Methods
Datasets
Non-small cell lung cancer samples, ADC(adenocarci-
noma) and SCC(squamous cell carcinoma) specimens
were obtained from pathological Stage I lung cancer
patients with no previous cancer history, and Normal
specimens were from patients undergoing lung resection
for suspicion of lung cancer but not carrying a diagnosis
of lung or other cancer. The protein lysates were pooled
into four pools: two from non-involved lung tissue (nor-
mal control, N = 20 and N = 19, respectively), one from
stage I adenocarcinomas (ADC, N = 20), and one from
stage I squamous cell carcinomas (SCC, N = 20). Each
pool was performed in 4 IEF/RPLC technical replicates.
All the fractions were analyzed by LC-MS/MS on an
LTQ-Orbitrap hybrid mass spectrometer equipped with
an Eksigent 1D Plus NanoLC pump and autosampler.
See Kikuchi et al paper for more detailed information
[41]. All the RAW data were downloaded from Proteo-
meCommons.org Tranche network [18], and were con-
verted to MGF format by ProteoWizard msconvert tool
[19] before submitted to search engines in our work
pipeline.
Construction of cancer fusion peptide database
Selecting potential gene pairs
There are N (N >= 20000) protein coding genes in the
human genome, even if we only consider situation of
paired gene fusion breaking points occurring in both ori-
ginal coding regions, N2 possibilities are not acceptable.
Two databases (ChimerDB [16] and CancerGeneCensus
[15]) have collected large amount of gene fusion events
either reported in cancer research literatures or predicted
from EST or next generation sequencing data. The
potential gene pairs for fusion in ChimerDB were down-
loaded from ChimerDB 2.0 and those in CancerGen-
eCensus were downloaded from COSMIC FTP site
(CosmicFusionExport_v58_150312). After filtering out
wrong gene symbols and removing redundant informa-
tion, 6259 unique gene pairs relating to 6174 unique
genes were curated as potential fusion peptide forming
gene pairs and used to construct CanProFu.
The concatenating of exons from two genes
To control the scale of the database, at this stage we
only considered the situation of fusion breaking points
falling into intron regions, since if the break point falls
in one exon region, each different location would gener-
ate a different translation frame. However intron regions
are supposedly to be cut out totally in translation, no
matter where the breaking points are as long as they fall
into introns (Additional File 6). Based on this rule we
constructed our fusion database. Primary tests discov-
ered some of the published fusion peptides such as
EML4:ALK [13] and NPM1:ALK [29], and proved that
our database is reliable (Additional File 7).
The necessity of including splicing peptides in the
database
Additional File 8 explains why splicing peptides should
be included in the database. In the case of two homolog
genes (left and right) with similar nucleotide sequences
and exons: left gene with exons A, B and C, and right
gene with exons A, B and E, obviously, the protein with
A and E exons could either be formed by the fusion
event of left gene and right gene or just be formed by
the splicing event of right gene. If our database con-
tained Fusion only, we would regard this peptide as
Fusion event but miss possible Splicing event. Therefore
splicing peptides of included genes were added into our
database, as competitor components. On the other
hand, new splicing events might be found in the data-
base as well, that adds one application to our database.
Database components
All the exon sequences, and also the additional informa-
tion such as exon ID, gene ID, exon position, gene posi-
tion, gene symbol and so on, of those 6259 gene pairs
(6174 genes) were obtained from Ensembl Genes 61
using BioMart [17]. The database contains five parts:
Fusion, Splicing, Annotated, Contaminated and Reversal.
See Figure 5 for the diagram. The number of the
sequences of each component was calculated and pro-
vided in Additional File 1. The construction of each
component is described briefly here:
Fusion
a) Each exon sequence of one gene in the gene pairs
was concatenated to each exon sequence of the other
gene. The upstream and downstream relationship
Figure 5 Five components of the constructed CanProFu
database. Known proteins from both Ensembl and Uniprot and
those potential contaminated proteins are used for competition
with the main components of the database: Fusion and Splicing.
The reversal sequences are used for FDR control.
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between the two genes of the gene pairs was also con-
sidered. The junction point position, exon ID, gene ID,
gene symbol and other information were recorded.
b) The concatenated sequences were translated into
amino acid sequence using three-frame translation. We did
not need to apply six-frame-translation like other works
because the direction of exons was already considered.
c) The translated amino acid sequences that don’t
contain gap (stop condon which is presented as a star in
the sequence) before the junction point were retained as
fusion peptides. We allow the sequences to have gaps
after the junction point, because some fusion events
might induce truncation of the translation.
d) The amino acid sequences were tryptic (cutting
after K and R, except when either is followed by P)
digested into peptides in silico, allowing at most one
mis-cleavage at each side of the fusion points.
e) Only the peptides with no less than 6 amino acids
crossing fusion points were kept.
Splicing
The reason why we needed to contain Splicing peptides
in the database was explained, and the steps to con-
struct Splicing peptides were basically the same as
Fusion except that, in the first step we only concate-
nated the exon sequences within one gene.
Annotated
The human protein sequences were downloaded from
uniprot (both Swiss-Prot and TrEMBL) [42] and
Ensembl.GRCh37.61 [17]. The Annotated protein
sequences were used as a competitor component of
Fusion and Splicing when searched by search engines.
Contaminated
Those proteins which may be present either by accident
or through unavoidable contamination of samples were
also contained as a competitor component. These pro-
tein sequences were downloaded from MaxQuant offi-
cial website [32].
Reversal
The reversal of all the sequences of the above four parts
were constructed for FDR control. The same peptides
were merged into one entry, and the peptides were
saved in fasta format, with the fusion point position, the
gene symbols, the exon ID and other information
recorded in the head line of the fasta format file.
Identification of fusion peptides and splicing
peptides
Database searching and FDR controlling
To reduce false positives and improve the reliability of
the results, two popular search engines, X!Tandem [20]
and Omssa [21], were used to score the spectrums to the
peptides. The default parameters of these search engines
were adopted, except that the parent monoisotopic mass
error was changed from ± 100da to ± 10da in X!Tandem.
Considering that the search space was expanded greatly,
and the normal FDR value such as 0.01 may not be suita-
ble, we minimized this value to 10-6 [8]. In practice, for
each raw file, the spectrums which were scored to Rever-
sal peptides were counted as F, and the others were
counted as T. The results of X!Tandem were sorted by
hypescore from high to low and sorted by e-value from
low to high for Omssa, then following FDR = 2*F/(T+F),
if FDR<=10-6, the spectrum matching peptide was con-
sidered to have passed the FDR controlling and remained
for the following analysis.
Determination of Fusion, Splicing or Annotated peptides
After FDR controlling, the peptides crossing the Fusion
or Splicing points were extracted as candidates. If the
candidates belonged to Fusion or Splicing and Anno-
tated simultaneously, they were classified as Annotated,
and if the candidates belonged to Fusion and Splicing
simultaneously, they were classified as Splicing. Then
the Fusion and Splicing peptides were blasted against
the NCBI nr database to ensure that they were not
known peptides. At the last step, only those peptides
which contained at least 3 amino acids at each side of
the fusion or splicing point were considered to be able
to represent fusion or splicing events and were kept for
further analysis.
Additional material
Additional File 1: The number of sequences of the five components
of our database. The Annotated part contained known protein
sequences from both Uniprot and Ensembl.
Additional File 2: The number of the peptides identified by X!
Tandem and Omssa. Each of the identified peptides could be classified
into one of the three types: Annotated which was found in the known
proteins, Fusion which crossed over the fusion point of two genes and
Splicing which crossed over the alternative splicing point.
Additional File 3: One example of peptide conservation. The peptide
was not in the known human protein, but was found in both Bos Taurus
and Desmodus rotundus. This peptide may indicate the alternative
splicing event of HNRPM.
Additional File 4: The characterized fusion or splicing peptides
identified from the MS/MS data. The two genes in the fusion events
are separated by colon. The value in the columns of No.X!Tandem and
No.Omssa column are the number of spectra of the peptide. A indicates
that the peptide was fully digested by trypsin and with no mis-cleavage.
B indicates that the peptide was fully digested but with one mis-
cleavage. C indicates that the peptide was semi-digested. E indicates that
the peptide was identified by totally different spectrums in X!Tandem
and Omssa search engines.
Additional File 5: Distribution of the identified fusion or splicing
events among subtypes of NSCLC: SCC (squamous cell carcinoma),
ADC (adenocarcinoma), and Normal lung samples. The value in the
columns of SCC, ADC and Normal column are the number of spectra of
the peptide.
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Additional File 6: The principle of constructing fusion peptide
database: when fusion points fall into intron regions. The diagram
showing both the breakpoints locate in the introns of the two genes.
The partial intron sequences (colored in pink and green) between ExonA
and ExonE could be removed exactly when translation like the way in
the dashed box in lower right corner or couldn’t be removed in lower
left corner.
Additional File 7: The principle of constructing fusion peptide
database: when fusion points fall into intron regions. Two protein
sequences of characterized fusion genes (EML4:ALK and NPM1:ALK) are
displayed and the peptides crossing the fusion point do exist in our
database where the partial introns were removed completely.
Additional File 8: The diagram indicates why the splicing peptide
should also be included in our database. If the splicing peptides from
ExonA and ExonE were not included, then we may regard the identified
A/E peptides to be surely from the fusion events. But in fact, they are
more likely the result from splicing events.
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